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OBJECTIVE—Obesity is associated with endocrine abnormali-
ties that predict the progression of insulin resistance to type 2
diabetes. Because skeletal muscle has been shown to secrete
proteins that could be used as biomarkers, we characterized the
secreted protein profile of muscle cells derived from extremely
obese (BMI 48.8  14.8 kg/m2; homeostasis model assessment
[HOMA] 3.6  1.0) relative to lean healthy subjects (BMI 25.7 
3.2 kg/m2; HOMA 0.8  0.2).
RESEARCH DESIGN AND METHODS—We hypothesized that
skeletal muscle would secrete proteins that predict the severity
of obesity. To test this hypothesis, we used a “bottom-up”
experimental design using stable isotope labeling by amino acids
in culture (SILAC) and liquid chromatography/mass spectometry/
mass spectometry (LC-MS/MS) to both identify and quantify
proteins secreted from cultured myotubes derived from ex-
tremely obese compared with healthy nonobese women.
RESULTS—Using SILAC, we discovered a 2.9-fold increase in
the secretion of myostatin from extremely obese human myo-
tubes. The increased secretion and biological activity of myosta-
tin were validated by immunoblot (3.16  0.18, P  0.01) and a
myoblast proliferation assay using conditioned growth medium.
Myostatin was subsequently shown to increase in skeletal muscle
(23%, P 0.05) and plasma (35%, P 0.05) and to correlate (r2
0.6, P  0.05) with the severity of insulin resistance.
CONCLUSIONS—Myostatin is a potent antianabolic regulator
of muscle mass that may also play a role in energy metabolism.
These findings show that increased expression of myostatin in
skeletal muscle with obesity and insulin resistance results in
elevated circulating myostatin. This may contribute to systemic
metabolic deterioration of skeletal muscle with the progression
of insulin resistance to type 2 diabetes. Diabetes 58:30–38,
2009
Obesity and type 2 diabetes are associated withendocrine abnormalities that are either precip-itated by or precede the onset of peripheralinsulin resistance (1). These include changes in
circulating proteins and peptides that produce endothelial
dysfunction, low-grade inflammation, and a prothrombotic
state, all of which contribute to increased cardiovascular
risk (2–4). Secreted proteins or the “secretome” constitute
an important class of biologically active molecules that are
released into circulation where they facilitate cross-talk
between organ systems. Because secreted proteins are
also involved in the progression of cardiovascular disease
and cancer, there is significant interest in mining the
secretome for novel biological markers (5). Whereas en-
docrine organs specialize in the secretion of proteins into
circulation, there is mounting evidence that adipose tissue
and skeletal muscle constitutively or intermittently secrete
bioactive proteins (6,7). In this study, we hypothesized
that skeletal muscle of extremely obese and insulin-
resistant women would secrete proteins into circulation
that act as prognostic or diagnostic biomarkers of obesity-
associated comorbidities. However, a top-down approach
toward identifying protein biomarkers in blood is ham-
pered by an abundant background of serum proteins,
wherein a secreted protein of interest may be diluted
several orders of magnitude (5,8). To overcome these
limitations, we adopted a bottom-up approach for charac-
terizing the skeletal muscle secretome using primary hu-
man muscle cells and stable isotope labeling by amino
acids in culture (SILAC), which allows for the identifica-
tion of muscle-specific proteins and for the quantification
of proteins between samples (5,8).
Primary human muscle cells are considered a valid
model for studying metabolic disorders with obesity and
type 2 diabetes because perturbances evident in vivo, such
as depressed lipid oxidation and abnormal gene expres-
sion, are retained in myotubes raised in culture, suggesting
an inherent characteristic (9–12). Herein, we describe our
primary finding that myostatin expression and secretion is
increased in both cell culture and skeletal muscle of
extremely obese human subjects.
RESEARCH DESIGN AND METHODS
To achieve the objectives of this study, we developed a bottom-up workflow
for identifying protein biomarkers secreted from obese and insulin-resistant
human skeletal muscle. In the first set of experiments, we identified the
differential secretion of myostatin from pure cultures of primary human
muscle cells using SILAC. The advantage of using this method is that it
allowed for the concentration and identification of low-abundance, muscle-
derived proteins in conditioned cell culture medium and for the quantification
of protein abundance between samples. In the second set of experiments, we
confirmed the increased secretion and biological activity of myostatin in
conditioned media from extremely obese human myotubes and the increased
abundance of myostatin in both skeletal muscle and plasma from extremely
obese human subjects. This experimental workflow allowed us to successfully
validate our cellular findings at the organ and systemic level.
The clinical characteristics of the four subject populations studied (lean,
obese, and extremely obese) are shown in Table 1. Research participants were
categorized on the basis of BMI and the classification of overweight and
obesity set forth by the National Institutes of Health. BMI criteria for the
normal-weight and extremely obese subjects were 24.9 and 40 kg/m2,
respectively. All subjects were sedentary and not exercising regularly. Skeletal
muscle samples were obtained after a 12-h overnight fast from the vastus
lateralis as previously described (13,14). With the exception of diabetic
patients, no subjects were taking any medications known to affect carbohy-
drate or lipid metabolism. The experimental protocols were approved by the
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East Carolina University Policy and Review Committee on Human Research,
and written informed consent was obtained from all subjects. Plasma glucose
was measured with an oxidation reaction using a glucose analyzer (YSI 2300
STAT Plus; YSI, Yellow Springs, OH), and plasma insulin was measured by
immunoassay (Access Immunoassay System; Beckman Coulter, Fullerton,
CA). The homeostasis model assessment (HOMA) for insulin resistance and
-cell function was calculated from fasting plasma glucose and insulin
concentrations (15). Estimates of insulin resistance using the HOMA have
been well documented as a reliable estimate of basal insulin resistance and
correlate well with the euglycemic-hyperinsulinemic clamp for evaluating
insulin sensitivity (15).
Stable isotope labeling and collection of secreted proteins. The advan-
tage of growing cells in stable isotope–labeled media is that all myotube-
derived proteins are uniformly labeled with 13C6-labeled Lys after three
passages, allowing secreted proteins and serum contaminants to be distin-
guished (5). Primary human muscle cells derived from three lean and
extremely obese (based on BMI) subjects were grown in medium with (obese
samples) or without (lean samples) 13C-Lys, and then secreted proteins were
collected and analyzed. The harvesting and culturing of satellite cells from
skeletal muscle biopsy material were conducted as previously described
(10,12). For metabolic labeling for quantitative proteomic profiling, cells were
incubated in Dulbecco’s modified Eagle’s medium (DMEM), which was
custom made without lysine (Invitrogen, Carlsbad, CA). Labeling media was
supplemented with 13C6-Lys (Invitrogen) for cells derived from extremely
obese donors, whereas unlabeled media were supplemented with regular
L-Lys for lean cells and 10% dialyzed fetal bovine serum (FBS) and 50 g/ml
gentamicin/amphotericin B. Cells were subcultured in collagen I–coated
75-cm2 flasks to passage 3, which has been shown previously to produce fully
labeled cells (8). Differentiation into myotubes was initiated at 90% confluence
using labeled and unlabeled differentiation medium containing 2% horse
serum with media changes every 2 days for a total of 9 days (16). There were
no obvious differences in the extent of myotube differentiation between
groups. To collect secreted proteins, cells were washed five times with PBS
buffer to remove excess equine serum proteins and then incubated in
serum-free labeled and unlabeled media for 18 h (8). Secreted proteins were
collected for 18 h to reduce the possibility of cell lysis, which would release
cytosolic proteins into serum-free medium (5,17). Conditioned media from
each of the labeled and unlabeled cultures were pooled in 50-ml tubes (BD
Biosciences Falcon, San Jose, CA), centrifuged at 300g and then at 1,000g, and
filtered through a 0.22-m nylon filter (Millipore, Bedford, MA) before a final
spin of 100,000g to remove any cell debris. Conditioned media were flash
frozen in liquid nitrogen, concentrated 100 times under vacuum, and desalted
against 10 mmol/l Tris-HCl, pH 7, using P6 Bio-Spin columns (Bio-Rad,
Hercules, CA); and the protein content was determined using the Bio-Rad
protein assay reagent following the manufacturer’s instructions. Secreted
protein fractions were then pooled and separated by SDS-PAGE, stained with
Coomassie, cut into six pieces corresponding to separate molecular weight
ranges (Fig. 1), and then digested with trypsin (Promega, Madison, WI) as
previously described (13).
LC-MS/MS, protein identification, and quantification. The resulting
peptide solutions were analyzed by LC-MS/MS at the southern Alberta mass
spectrometry center at the University of Calgary (Calgary, AB, Canada).
Chromatographic separations of peptides were performed with a C18 analyt-
ical column using an Agilent 1100 nanoLC system (Agilent Technologies,
Santa Clara, CA). Peptides were loaded onto an enrichment and eluted with
0.2% formic acid and 10% water in acetonitrile over 50 min. The analytical
column was connected online to a Qstar XL Hybrid quadrupole time-of-flight
(TOF) mass spectrometer fitted with a nanospray ion source (Applied
Biosystems, Foster City, CA). TOF MS experiments were performed in
positive ion mode over an m/z range of 400–1,500. Automated tandem MS
TABLE 1
Clinical characteristics of donor subjects for muscle cell culture
Lean Obese
Extremely
obese
n 6 5 9
Age (years) 41.2 5.0 46.8 4.2 45.8 3.9
BMI (kg/m2) 25.7 1.3 32.3 1.1* 48.9 4.9*
Glucose (mg/dl) 97.0 6.0 91.1 2.9 97.7 4.4
Insulin (U/ml) 3.3 0.9 7.2 2.7 14.6 2.7*
HOMA 0.8 0.2 1.3 0.6 3.6 1.0*
Data are means  SE. *Significant differences at P  0.05, lean vs.
obese and extremely obese subjects.
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FIG. 1. LC-MS/MS identification and quantification of 13C6-Lys and unlabeled secreted proteins from lean and extremely obese primary human
myotubes. A: Proteins from 18-h conditioned, serum-free media from unlabeled (lean) and 13C6-Lys (extremely obese) myotubes were combined
1:1 and resolved by 4–16% SDS-PAGE. B: The base peak chromatograph showing overall peak intensities and retention time of all the peptides
extracted from a gel slice between 37 and 15 kDa. C: A peptide eluting at 31.8 min as a doublet at m/z 706.4 and 709.4, corresponding to the
unlabeled and 13C6-Lys peptide from human GAPDH. The peptide sequence shown on top of the spectrum was obtained by MS/MS analysis. The
labeled and unlabeled peptides are 3 Da apart in a 1:1 ratio and agree with one 13C6-Lys residue in the doubly charged peptide. (Please see
http://dx.doi.org/10.2337/db08-0943 for a high-quality digital representation of this figure.)
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analyses were carried out using a standard data-dependent configuration, in
which the three most intense peptides (2 or 3 charge states) in an MS scan
were automatically selected for sequencing. Protein searches were performed
against the human NCBInr and SwissProt databases using the Mascot distiller
(Matrix Science, London) using the Mascot search algorithm. The mass
tolerance for the precursor peptide ion was set at 200 parts per million, and
the mass tolerance for the MS/MS fragment ions was set to 0.5 Da. Quantita-
tion was performed manually according to the manufacturer’s instructions
(Invitrogen). Briefly, we used the Mascot peptide summary list generated for
each LC-MS/MS run and Analyst QS 1.1 Software (Applied Biosystems) to
analyze selected ion chromatograph data from the raw WIFF file generated by
the LC-MS/MS analysis. The retention time and protein identification for each
peptide were then confirmed by the y ions from each MS/MS and the relative
abundance of selected peptide pairs (Figs. 1 and 2) calculated as previously
described (8). The search parameters allowed for variable modifications,
including amidomethylation of cysteine, oxidation of methionine, and pres-
ence of 13C6-Lys. Secreted proteins had to have a minimum of one
13C6-Lys
peptide identified with high confidence and had to be verified by manual
inspection for having a consecutive series of y ions (8).
Western blot analysis of conditioned media, skeletal muscle, and
plasma. Myostatin protein levels in conditioned media, muscle cells, whole
skeletal muscle, and plasma were verified using Western immunoblot. To
collect secreted proteins for quantifying myostatin levels, cells (9-day myo-
tubes) were washed five times with PBS and incubated with serum-free
Optimem (Invitrogen) for an additional 24 h as described previously (18,19).
Optimem medium contains growth factors that promote cell survival with
extended incubations and is specifically designed for the characterization of
secreted proteins. Conditioned medium was decanted into 50-ml tubes (BD
Biosciences Falcon), centrifuged at 300g and then at 1,000g, and filtered
through a 0.22-m nylon filter (Millipore) before a final spin of 100,000g to
remove any remaining cell debris. Conditioned media were then flash frozen
in liquid nitrogen and lyophilized under vacuum and then precipitated with
10% trichloroacetic acid followed by several washes with 20°C acetone as
described previously (18). In all, 50 g protein was collected per sample,
separated by SDS-PAGE, and transferred to Immobilon-P PVDF Membrane
(Millipore).
For Western blot analysis of myostatin levels in muscle, nitrogen-pulver-
ized skeletal muscle or myotubes were extracted using digitonin buffer (10
mmol/l PIPES, 0.015% digitonin, 300 mmol/l sucrose, 100 mmol/l NaCl, 3
mmol/l MgCl2, 5 mmol/l EDTA, and 1 mmol/l protease inhibitor [phenylmeth-
ylsulfonyl fluoride], pH 6.8) with gentle inversion at 4°C for 40 min (20). This
was then centrifuged at 8,000g for 20 min to remove insoluble cellular debris.
Protein concentration was determined using the Bio-Rad protein assay dye
reagent, following the manufacturer’s instructions (Bio-Rad, Hercules, CA).
Twenty micrograms cellular protein (19,21) was then separated by SDS-PAGE
and transferred to Immobilon-P PVDF Membrane (Millipore). Membranes
were stained with Ponceau S to confirm equal loading and transfer efficiency.
To analyze plasma proteins for Western blot analysis, 2 l plasma was
diluted 1:10 in PBS, and 100 g protein was loaded on precast 4–12% gradient
SDS-PAGE gels (Invitrogen) and transferred to Immobilon-P PVDF Membrane
(Millipore). The primary antibody used in this study was a polyclonal
anti-myostatin antibody (R&D Systems, Minneapolis, MN) raised against
Escherichia coli–derived, recombinant whole-mouse myostatin in goats. We
chose this specific antibody both for its ability to reliable detect human
myostatin and to neutralize myostatin activity in a biological assay. The
primary antibody used to detect glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) was a mouse monoclonal antibody (Abcam, Cambridge, MA).
Membranes were incubated in 1/1,000 in primary antibody in Tris-buffered
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FIG. 2. LC-MS/MS identification and quantification of secreted myostatin protein. A: The top spectrum shows a peptide doublet at m/z 571.8 and
574.8 corresponding to unlabeled and 13C6-Lys peptides from human myostatin. The labeled and unlabeled peptides are 3 Da apart in a 3:1 ratio
and agree with one 13C6-Lys residue in the doubly charged peptide. The peptide sequence shown on top of the spectrum was obtained by MS/MS
analysis of the fragmented peptide. B: Shown in bold an underlined are the relative positions of the other myostatin peptides identified in the
primary sequence of human myostatin.
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saline with Tween for 20 h at 4°C. After washing, primary antibodies were
detected using horseradish peroxidase–conjugated anti-goat secondary anti-
bodies (Santa Cruz Biotechnology, Santa Cruz, CA) at a dilution of 1/5,000 and
a SuperSignal West Pico Chemiluminescent Substrate (Pierce, Rockford, IL).
Images were acquired and quantified using a ChemiGenius Bioimaging System
(Syngene, Frederick, MD).
Myoblast proliferation assay. To assess the biological activity of secreted
myostatin protein in conditioned media, we used a myoblast proliferation
assay as previously described, which is based on the ability of myostatin to
inhibit progression of myoblasts from the G1- to S-phase of the cell cycle
(18,22). Briefly, cells were seeded at 1,000 cells/well in 96-well plates (Nunc
Nalgene, Rochester, NY) in pooled 48-h conditioned growth medium (DMEM
plus 10% FBS) from human muscle cells derived from three lean and
extremely obese subjects. Forty-eight hours has been shown to be sufficient
time for the accumulation of secreted myostatin in conditioned media (18,22).
As a control, cells were also proliferated in conditioned media that were
preincubated with 20 g/ml anti-myostatin antibody or in unconditioned
growth medium. This concentration of anti-myostatin antibody has been
shown by the manufacturer (R&D Systems) to neutralize up to 30 ng/ml active
myostatin protein. At daily intervals over a 4-day period, proliferating myo-
blasts were trypsinized, and cell densities were determined (in quadruplet)
using a hemocytometer (Hausser Scientific, Horsham, PA).
Statistical analysis. For comparisons of myostatin abundance in muscle and
plasma, we used an independent t test with two-tailed distribution with the
significance level set to P  0.05. For comparison of myostatin protein
abundance in conditioned medium and cells and myoblast proliferation
assays, we used a Kruskal-Wallis One Way ANOVA using SigmaStat (Systat,
San Jose, CA) and a Tukey’s post hoc test for multiple comparisons with P 
0.05 or 0.01 indicating significance. Linear regression analysis were conducted
using the least squares method (SigmaPlot) with P 0.05 as the probability of
being wrong in concluding that there is a true association.
RESULTS
Analysis of secreted proteins. The 42 proteins identified
in 18-h conditioned, serum-free media from primary cul-
tured human myotubes are listed in Table 2. Of these, 28
have been previously shown to be secreted. The remaining
14 are metabolic enzymes, cytoskeletal, or contractile
proteins. The presence of intracellular proteins in condi-
tioned culture media has been described in numerous
surveys of protein secretion (8,17,23). Several of the
proteins secreted by primary human myotubes have been
described previously in studies of differentiating mouse
myotubes (17) and human adipose (23) and retinal pig-
ment epithelial cells (8). Indeed, two of these proteins,
Type I Collagen and Osteonectin, are secreted by all three
(Table 2), suggesting that they are essential secreted
components of many cell types. It is also worth noting that
13 of the 28 secreted proteins were predicted using in
silico modeling of the human skeletal muscle secretome
(24).
In Fig. 1, we show a representative LC-MS chromato-
graph (Fig. 1B) and the identification of a peptide doublet
from Human GAPDH (Fig. 1C) for unlabeled and labeled
peptide pairs at m/z 706.4 and 709.4, respectively. The
difference in the mass between these doubly charged ions
is 3 Da, indicating that the peptide should contain one
lysine residue. According to the ratio of the monoisotopic
intensities, GAPDH was secreted in an 1:1 ratio from
lean relative to extremely obese myotubes. GAPDH has
also been shown to be secreted into the growth media of
a number of cell lines (25). GAPDH was therefore chosen
as a loading control for subsequent Western immunoblot
validation of myostatin secretion. In Fig. 2, we show a
mass spectrum obtained for a peptide unique to myostatin
protein with peaks for unlabeled and labeled peptide pairs
at m/z 571.8 and 574.8, respectively. The difference in the
mass between these doubly charged ions is 3 Da, indicat-
ing that the peptide should contain one lysine residue. The
sequence of the peptide was confirmed by the MS/MS
analysis of the peptides and comparison of the y and b ions
as described previously (8). According to the ratio of the
peptide intensities, the secreted ratio of myostatin was
calculated as 3:1 from extremely obese versus lean myo-
tubes. The other labeled peptides identified from myosta-
tin (Fig. 2B) did not appear to have unlabeled companion
peptides, indicating significantly higher abundance in con-
ditioned media from extremely obese cells.
Western blot validation of myostatin secretion. Be-
cause myostatin was identified as the most robustly differ-
entially secreted protein in conditioned medium (Fig. 2), it
became the main focus for validation. As shown in Fig. 3,
there were significant differences in the secretion of the
26-kDa mature form of myostatin into conditioned me-
dium from extremely obese (3.16  0.18, P  0.01)
myotubes relative to those derived from healthy nonobese
subjects. This relative difference approximates the 3:1
ratio calculated using SILAC (Fig. 2). Unlike other studies
(18), we did not detect the secretion of the 52-kDa
precursor form of myostatin. This may be because of our
choice of antibody or the exceptional care we took to
minimize cell lysis. Finally, human GAPDH protein was
detected using SILAC as being secreted in a 1:1 ratio
(Fig. 1C) and was selected as a loading control for
secreted proteins. As shown in Fig. 2A, GAPDH was
detected in similar amounts in conditioned media from
lean, obese, and extremely obese cells when compared
against differences in myostatin abundance.
Myostatin expression in cultured myotubes, muscle,
and plasma. Because of the increased myostatin secre-
tion into conditioned media from extremely obese relative
to lean cells (Fig. 3), we also determined the expression of
myostatin protein in cultured myotubes, skeletal muscle,
and plasma. In Fig. 4, we show that expression of the
52-kDa myostatin precursor protein was significantly ele-
vated (2.0  0.12, P  0.01) in cells cultured from
extremely obese compared with lean nonobese donors.
The 40-kDa myostatin propeptide was similarly elevated in
extremely obese myotubes. Although the mature 26-kDa
myostatin peptide was clearly increased in extremely
obese cells, it was only sporadically detected (three of
eight samples). The processing of the 52-kDa myostatin
precursor protein produces an NH2-terminal, 40-kDa laten-
cy-associated peptide (LAP) and the biologically active
26-kDa COOH-terminal dimer (19). These findings are
consistent with those of previous studies: that myostatin is
rapidly processed and secreted from cultured muscle cells
compared with mature muscle (19,22). Because both the
expression and secretion of myostatin was increased in
cells derived from extremely obese human donors, we also
studied its expression in skeletal muscle and plasma in a
separate patient cohort.
In Fig. 5, we show a 23% (P 0.05) increase in myostatin
52-kDa precursor protein and a 35% increase in the 26-kDa
dimer, respectively (P  0.05), in extremely obese muscle
and plasma relative to lean samples. Unlike myotubes, the
52-kDa precursor protein has been shown to be the most
abundant immunoreactive species in mature skeletal mus-
cle (19,21). Linear regression analysis of myostatin protein
levels relative to HOMA (Fig. 6A) revealed a significant
correlation (r2  0.6, P  0.03), although it seems to
correlate better with body mass (Fig. 6B) (r2  0.737, P 
0.01), which is not entirely surprising given the extreme
differences in BMI between these groups.
Myoblast proliferation bioassay for myostatin. Myo-
statin reduces muscle mass in vivo and by inhibiting the
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proliferation of myoblasts (18,19,22). We cultured mouse
C2C12 myoblasts in the presence of 48-h conditioned
growth media from lean and extremely obese cultured
myotubes (Fig. 7). To differentiate the effects of myostatin
from other secreted molecules, we preincubated media
with neutralizing concentrations of anti-myostatin anti-
body. In Fig. 7, we show a significant inhibition in the
proliferation of myoblasts grown in conditioned medium
from the extremely obese myotubes. These observations
are consistent with previous studies of the growth-inhib-
iting effects of myostatin on myoblast proliferation
(18,19,22). After 2 days, these cells were proliferating
TABLE 2
List of proteins identified in conditioned media of primary human myotubes
SwissProt Peptides Secreted Evidence
Immune response/complement
Complement component 4B P0C0L5 7 Yes 8,24
Complement factor H-related 5 Q9BXR6 2 Yes 8
Growth factors/chemokines
Epidermal growth factor P01133 2 Yes Swiss-Prot
Fibroblast growth factor 17 O60258 2 Yes Swiss-Prot
Insulin-like growth factor 1 Q59GC5 1 Yes 24
Interferon 	2/1 Q14608 1 Yes Swiss-Prot
Lymphotactin P47992 1 Yes Swiss-Prot
Monocyte chemotactic protein 4, MCP-4 Q99616 2 Yes Swiss-Prot
Myostatin Q8HY52 3 Yes Swiss-Prot
Cell adhesion/extracellular matrix
Collagen, type III, 	1 P02461 2 Yes 17
Collagen, type IV, 	2 P08572 4 Yes 17,24
Collagen, type IV, 	3 Q01955 2 Yes 17,24
Collagen, type I, 	1 P02452 5 Yes 8,17,23,24
Extracellular matrix protein 2 O94769 1 Yes 23,24
Laminin, 	2 P24043 4 Yes 24
Laminin, 	3 Q16787 3 Yes 24
Tenascin C P24821 5 Yes 24
Tenascin XB Q5JNX3 2 Yes 24
Aggrecan core protein P16112 2 Yes Swiss-Prot
S100 calcium-binding protein A6/calcyclin P06703 3 Yes Swiss-Prot
Osteonectin/SPARC P09486 18 Yes 17,23,24
Vimentin P08670 18 Yes 17
Galectin-1 P09382 6 Yes 17
	-Crystallin P02511 2 Yes Swiss-Prot
Protease and protease inhibitors
Plasma protease (C1) inhibitor precursor P05155 2 Yes 23
Metalloproteinase inhibitor 1 precursor P01033 12 Yes 8,24
Metalloproteinase inhibitor 2 precursor P16035 12 Yes 24
Bone morphogenetic protein 1 P13497 2 Yes Swiss-Prot
Ubiquitin P62988 4 Yes 17
Intracellular, contractile, and shed proteins
Dystonin Q5TBT2 12 No
Fetal myosin heavy chain Q9Y623 4 No
Glyceraldehyde-3-phosphate dehydrogenase P04406 3 Yes 25
Integrin, 	6 P23229 2 No
Myosin binding protein C, fast type Q14324 3 No
Phosphofructokinase, muscle P08237 5 No
Titin Q8WZ42 32 No
Triosephosphate isomerase 1 P60174 6 No
Vinculin P18206 6 No
Tropomyosin  P07951 15 No
SH3 binding glutamic acid–rich protein Q5T122 2 No
Desmin Q549R9 3 No
Myosin light chain 1 P14649 3 No
-Coat protein P53618 2 No
Stathmin P16949 4 No
Triosephosphate isomerase P60174 15 No
Ubiquitin P62988 4 No
Phosphoglycerate mutase 1 P18669 4 No
	-Crystallin P02511 2 No
Nebulin EAX11499 6 No
Myoglobin Q8WVH6 3 No
Proteins identified using SILAC are shown with their accession numbers, number of peptides identified, and literature evidence for being
secreted proteins.
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significantly more slowly (2.3  0.11-fold, P  0.05) than
control cells. This inhibition of proliferation became more
pronounced after 3 days of incubation when there were
significant differences in lean compared with obese con-
ditioned medium (2.06  0.11-fold, P  0.01) and between
cells grown in anti-myostatin antibody precleared medium
(1.5  0.15-fold, P  0.01). Interestingly, antibody-
preincubated cells grown in obese medium grow at the
same rate as control cells and faster than lean cells until
day 4, suggesting the presence of proliferation-promoting
factors in obese conditioned media. Trypsinized cells
cultured in lean and obese conditioned medium were
routinely stained with Trypan blue and showed no signif-
icant differences in the percentage of viable cells.
DISCUSSION
Although skeletal muscle is not considered a secretory
organ per se, there is a growing body of evidence that it
may constitutively or intermittently secrete biologically
active molecules in health and disease (17,24,26,27). The
goal of this study was to identify proteins that are secreted
into circulation by muscle that could be used as biological
markers for the severity of obesity. Here, we report that
myostatin is expressed and actively secreted into circula-
tion from cultured muscle cells and mature skeletal mus-
cle from extremely obese relative to healthy nonobese
subjects. This is the first known quantitative description of
myostatin protein level with obesity and insulin resistance
in human tissue. These results confirm and expand on
previous studies describing changes in myostatin mRNA
expression in a number of experimental models of obesity
and weight loss (28–30).
Myostatin is a potent antianabolic inhibitor of muscle
growth and development belonging to the transforming
growth factor- (TGF-) family. As with other TGFs,
myostatin is translated as a precursor protein that is
cleaved to yield a NH2-terminal LAP and COOH-terminal
peptide dimer that is from the cell (18,19). The mature
myostatin dimer is secreted from muscle in a noncovalent
association with the LAP, which protects it from degrada-
tion and maintains its active conformation. Mature myo-
statin is released from the LAP by the extracellular
matrix–associated bone morphogenetic protein-1/tolloid
metalloprotease, which is thought to activate both locally
acting (paracrine) and circulating (autocrine) forms of
myostatin. The free mature myostatin peptide then binds
to the activin type II B receptor through which it exerts its
well-characterized antianabolic effects on resident muscle
myoblasts by inhibiting their progression from the G1- to
S-phase of the cell cycle (18,22). This is why the deletion
or inhibition of circulating myostatin produces a hyper-
muscular phenotype (31,32).
Myostatin was first hypothesized to play a role in
metabolism after it was observed that hypermuscular
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FIG. 3. Myostatin secretion is increased from extremely obese primary
human myotubes. Equal amounts of protein from 24-h–conditioned,
serum-free media resolved by 15% SDS-PAGE. Myostatin (A) and
GAPDH (B) protein were detected with polyclonal goat anti-myostatin
and monoclonal mouse anti-GAPDH antibodies, respectively. The ma-
ture form of myostatin is indicated in a representative blot, and the
molecular masses of the detected bands are indicated. Number of
replicated are indicated for each sample, and the asterisk indicates
significant differences (P < 0.05). Data are normalized to average lean
expression level  SE. ExOb, exobese. (Please see http://dx.doi.org/10.
2337/db08-0943 for a high-quality digital representation of this figure.)
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FIG. 4. Myostatin protein is increased in extremely obese primary
human myotubes. Equal amounts of total protein from primary human
myotubes were resolved by 15% SDS-PAGE. A: Myostatin protein was
detected with goat polyclonal anti-myostatin antibodies. Precursor,
mature, and LAP forms of myostatin are indicated in a representative
blot. Molecular masses of the detected bands are indicated. B: Only the
52-kDa precursor form of myostatin was quantified; however, the LAP
appeared to follow a similar expression profile. Small amounts of the
26-kDa mature myostatin were detected only in extremely obese
myotubes. Number of replicated are indicated for each sample, and the
asterisk indicates significant differences (P < 0.05). Data are normal-
ized to average lean expression level  SE. (Please see http://dx.doi.
org/10.2337/db08-0943 for a high-quality digital representation of this
figure.)
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myostatin null mice have reduced fat mass and are seem-
ingly immune to dietary-induced insulin resistance (33,34).
Whether this is due solely to increased lean muscle mass
or other metabolic effects of reduced circulating myostatin
have yet to be determined (33). Recent studies, however,
have shown that myostatin inhibits glucose uptake in
placental cell lines, suggesting that it may contribute to
systemic insulin resistance with obesity (35). Others have
implicated myostatin in a network of genes potentially
regulated by insulin with extreme obesity (30). Severe
caloric restriction and starvation have also been shown to
increase myostatin expression in skeletal muscle, presum-
ably to reduce the metabolic burden of a large muscle
mass (36). The evolutionary context for this model is that
under starvation conditions, increased circulating myosta-
tin is survivalistic because it preserves brain function, and
hence the ability to forage for food, by maintaining blood
glucose (37). Considering these important observations,
we hypothesize that skeletal muscle insulin resistance
induces myostatin expression in response to a cellular
state of starvation. Or put another way, the metabolic
milieu of obese skeletal muscle may be similar to that of
starving muscle because of the insulin-resistant state in
which glucose uptake is severely constrained and the
oxidative catabolism of lipid is reduced or incomplete;
however, this hypothesis has not been tested (10,13,14,38).
It has also been shown that myostatin expression in
muscle is reduced acutely with endurance and resistance
exercise (39). Because physical inactivity and a glycolytic
fiber type distribution are common features of obesity,
elevated myostatin levels could also be secondary to
sedentary lifestyle (40,41). Because insulin resistance is
not consistently maintained in primary cultured muscle
cells, increased myostatin expression could be an inherent
characteristic of the extremely obese (14). Finally, al-
though we have shown correlation between muscle insulin
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FIG. 7. Proliferation rate of C2C12 mouse myoblasts grown in human
myotube-conditioned growth medium. Equal numbers of cells were
grown in lean or extremely obese human myotube conditioned growth
medium, which was preincubated with or without goat polyclonal
anti-myostatin antibodies to neutralize myostatin activity. Plotted
values represent the average of three experiments  SD. Asterisks
indicate significant differences (P < 0.05). Control cells were grown in
unconditioned growth medium.
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resistance and myostatin expression in muscle, a causal or
mechanistic relationship has not been established.
Although there is clearly a loss of muscle mass with
frank type 2 diabetes (42,43), it is unclear whether in-
creased circulating myostatin plays a direct role in the
metabolic deterioration of skeletal muscle with obesity
and insulin resistance. Supporting a role for myostatin in
diabetic muscle atrophy is the high level of myostatin
expression in ob/ob diabetic mice that have both reduced
muscle mass and fiber cross-sectional area (33,44,45).
In summary, we have shown increased expression of
myostatin protein with extreme obesity at the cellular,
organ, and systemic level. To our knowledge, this is the
first identification of a noncancer biomarker using quanti-
tative secreted protein profiling (46–48). Future studies
will test our hypothesis that myostatin expression is
induced by insulin resistance in muscle.
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